Literature DB >> 19909663

Anxious depression: clinical features and treatment.

Sanjai Rao1, Sidney Zisook.   

Abstract

Anxious depression has been conceptualized in at least two related but separate ways: 1) major depressive disorder with at least one comorbid Axis I anxiety disorder and 2) major depressive disorder with a high level of anxiety with or without one or more comorbid Axis I anxiety disorders. Using either definition, patients with anxious depression seem to have a more chronic course of illness, an increased incidence of suicidal thoughts and behavior, greater functional and occupational impairment, and poorer response to treatment. Multiple classes of medications are used to treat anxious depression, most commonly first- and second-generation antidepressants, atypical antipsychotics, and benzodiazepines. Certain patients with anxious depression may require lower starting doses, more gradual dose escalations, higher end point doses, longer duration of treatment, and/or early augmentation with other agents. Nonpharmacologic treatments such as targeted psychotherapy and preventative stepped-care approaches also may be effective. Well-conceived, randomized controlled treatment trials are necessary to make further gains in the management of patients with anxious depression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909663     DOI: 10.1007/s11920-009-0065-2

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  45 in total

Review 1.  Use of bupropion in combination with serotonin reuptake inhibitors.

Authors:  Sidney Zisook; A John Rush; Barbara R Haight; Dawn C Clines; Carol B Rockett
Journal:  Biol Psychiatry       Date:  2005-09-13       Impact factor: 13.382

2.  Comorbid panic disorder and major depression: implications for cognitive-behavioral therapy.

Authors:  P D McLean; S Woody; S Taylor; W J Koch
Journal:  J Consult Clin Psychol       Date:  1998-04

3.  Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial.

Authors:  Jürgen Unützer; Wayne Katon; Christopher M Callahan; John W Williams; Enid Hunkeler; Linda Harpole; Marc Hoffing; Richard D Della Penna; Polly Hitchcock Noël; Elizabeth H B Lin; Patricia A Areán; Mark T Hegel; Lingqi Tang; Thomas R Belin; Sabine Oishi; Christopher Langston
Journal:  JAMA       Date:  2002-12-11       Impact factor: 56.272

4.  Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.

Authors:  Madhukar H Trivedi; A John Rush; Bradley N Gaynes; Jonathan W Stewart; Stephen R Wisniewski; Diane Warden; Louise Ritz; James F Luther; Diane Stegman; Joanne Deveaugh-Geiss; Robert Howland
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

5.  Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder.

Authors:  M Zimmerman; W McDermut; J I Mattia
Journal:  Am J Psychiatry       Date:  2000-08       Impact factor: 18.112

6.  Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study.

Authors:  Tarja K Melartin; Heikki J Rytsälä; Ulla S Leskelä; Paula S Lestelä-Mielonen; T Petteri Sokero; Erkki T Isometsä
Journal:  J Clin Psychiatry       Date:  2002-02       Impact factor: 4.384

7.  Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

Authors:  Boadie W Dunlop; Paula G Davis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 8.  What is the genetic relationship between anxiety and depression?

Authors:  John M Hettema
Journal:  Am J Med Genet C Semin Med Genet       Date:  2008-05-15       Impact factor: 3.908

9.  Co-occurrence of depression and anxiety in elderly subjects aged 90 years and its relationship with functional status, quality of life and mortality.

Authors:  Gerda M Van der Weele; Jacobijn Gussekloo; Margot W M De Waal; Anton J M De Craen; Roos C Van der Mast
Journal:  Int J Geriatr Psychiatry       Date:  2009-06       Impact factor: 3.485

10.  A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.

Authors:  Jay D Amsterdam
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

View more
  14 in total

1.  Supplemental dietary choline during development exerts antidepressant-like effects in adult female rats.

Authors:  Melissa J Glenn; Raven S Adams; Lauren McClurg
Journal:  Brain Res       Date:  2012-01-17       Impact factor: 3.252

2.  Modest abuse-related subjective effects of zolpidem in drug-naive volunteers.

Authors:  Stephanie C Licata; Yasmin Mashhoon; Robert R Maclean; Scott E Lukas
Journal:  Behav Pharmacol       Date:  2011-04       Impact factor: 2.293

Review 3.  Neurobiology of anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2013-03-11       Impact factor: 6.505

4.  On the differential diagnosis of anxious from nonanxious major depression by means of the Hamilton Scales.

Authors:  George Konstantakopoulos; Vasilios G Masdrakis; Manolis Markianos; Panagiotis Oulis
Journal:  ScientificWorldJournal       Date:  2013-10-27

5.  Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.

Authors:  Leslie Citrome; Carl P Gommoll; Xiongwen Tang; Rene Nunez; Maju Mathews
Journal:  Int Clin Psychopharmacol       Date:  2015-03       Impact factor: 1.659

6.  Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder.

Authors:  Ji Hyun Baek; Hee-Jin Kim; Maurizio Fava; David Mischoulon; George I Papakostas; Andrew Nierenberg; Jung-Yoon Heo; Hong Jin Jeon
Journal:  Psychiatry Investig       Date:  2016-05-18       Impact factor: 2.505

7.  Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.

Authors:  Ligen Shi; Jingyi Wang; Shenbin Xu; Yunrong Lu
Journal:  Drug Des Devel Ther       Date:  2016-11-25       Impact factor: 4.162

8.  maLPA1-null mice as an endophenotype of anxious depression.

Authors:  R D Moreno-Fernández; M Pérez-Martín; E Castilla-Ortega; C Rosell Del Valle; M I García-Fernández; J Chun; G Estivill-Torrús; F Rodríguez de Fonseca; L J Santín; C Pedraza
Journal:  Transl Psychiatry       Date:  2017-04-04       Impact factor: 6.222

9.  Clinical relevance of vilazodone treatment in patients with major depressive disorder: categorical improvement in symptoms.

Authors:  Larry Culpepper; Maju Mathews; Razi Ghori; John Edwards
Journal:  Prim Care Companion CNS Disord       Date:  2014-01-30

10.  Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.

Authors:  Michael E Thase; Dalei Chen; John Edwards; Adam Ruth
Journal:  Int Clin Psychopharmacol       Date:  2014-11       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.